📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-08 15:47
690 analysed today
690
Today
133,579
All-time analysed
40,122
Positive
6,284
Negative
79,354
Neutral
7,751
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Ishita Drugs Commits Rs 10 Cr to Facility Upgradation; Re-appoints Director
Ishita Drugs has announced a major manufacturing facility upgradation to comply with Revised Schedule M standards, involving a total commitment of approximately Rs 10 crore. To date, the company has spent Rs 4.35 crore on civil works and a new warehouse, with another Rs 5.65 crore in equipment orders issued. This project is highly material, representing approximately 67% of the company's TTM revenue of Rs 15 crore and 83% of its net worth. The board also approved the re-appointment of promoter Mrs. Abha Agrawal as a director and is currently negotiating with banks for project financing.
Confidence: HIGH
What changedThe company provided a concrete financial update on its ongoing facility upgradation and formalized the re-appointment of a key promoter-director.
Why it mattersThe Rs 10 crore investment is a major undertaking for a company with a Rs 23 crore market cap, aimed at meeting revised regulatory standards (Schedule M) which is critical for continued operations and potential growth in the pharma sector.
Capex spent to date: Rs 4.35 crCapital contracts issued: Rs 5.65 crTotal project vs TTM Revenue: ~67%Total project vs Net Worth: ~83%Market Capitalization: Rs 23 cr
📅 Short termPositive sentiment expected as the company demonstrates commitment to regulatory compliance and capacity expansion, though funding details remain a key variable.
📈 Long termStructural improvement in manufacturing capabilities and regulatory compliance, though debt levels may rise if bank financing is secured for this large-scale project.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Funding risk (bank negotiations ongoing)
- Execution risk for the upgradation project
- High concentration of promoter family in management
Key Highlights
Rs 4.35 crore already spent on renovation of existing buildings and construction of a new warehouse block.
Rs 5.65 crore in capital contracts and orders issued for various utilities and equipment.
Total project commitment of ~Rs 10 crore represents ~67% of TTM revenue (Rs 15 Cr).
Re-appointment of Mrs. Abha Agrawal as Non-Executive Director notwithstanding her attaining the age of 75 years.
Company is actively negotiating with banks to raise funds for financing the remaining upgradation project.
👀 What to Watch
Monitor the successful closure of bank financing for the project and the timeline for completion of the manufacturing facility extension to ensure no regulatory disruptions.
Rs 10 Cr Capex for Facility Upgradation; Q1 FY27 Results Approved
Ishita Drugs & Industries has announced a major manufacturing facility upgradation project to comply with Revised Schedule M standards. The company has already spent Rs 4.35 crore on renovation and new construction, with an additional Rs 5.65 crore in capital contracts already issued. This total commitment of Rs 10 crore is highly significant, representing approximately 67% of the company's TTM revenue of Rs 15 crore. The company is currently negotiating with banks to secure financing for the project.
Confidence: HIGH
What changedThe company has moved into the execution phase of a major facility upgrade, committing capital equivalent to a significant portion of its annual revenue.
Why it mattersFor a micro-cap company with Rs 15 cr revenue, a Rs 10 cr investment is transformative. Compliance with Revised Schedule M is essential for regulatory standing and can potentially lead to higher-margin business or export opportunities.
Capex spent to date: Rs 4.35 crCapital contracts issued: Rs 5.65 crTotal Project vs TTM Revenue: ~67%Total Project vs Net Worth: ~83%TTM Revenue: Rs 15 cr
📅 Short termThe market is likely to view the substantial capex commitment as a sign of long-term growth intent, though the lack of specific Q1 P&L figures in the text may limit immediate momentum.
📈 Long termIf executed successfully, the upgraded facility could re-rate the business by allowing it to handle more complex pharmaceutical manufacturing and meet stricter regulatory requirements.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk of the ongoing construction
- Financing risk as bank negotiations are still active
- Potential for increased interest costs given the current zero-debt status
Key Highlights
Rs 4.35 crore already spent on renovation of existing buildings and construction of new blocks
Rs 5.65 crore in capital contracts and orders issued for utilities and equipment
Total project visibility of Rs 10 crore represents ~67% of TTM revenue (Rs 15 cr)
Upgradation project is aimed at compliance with Revised Schedule M manufacturing standards
Board approved re-appointment of promoter Mrs. Abha Agrawal as Non-Executive Director
👀 What to Watch
Monitor the successful closure of bank financing and the timeline for the completion of the manufacturing facility upgrade. Watch for any impact on production during the renovation phase in upcoming quarterly results.
Ishita Drugs to invest ₹10 Cr in facility upgrade; ₹4.35 Cr already spent
Ishita Drugs & Industries has announced a significant manufacturing facility upgrade to comply with Revised Schedule M standards. The company has already spent ₹4.35 crore on construction and has issued capital contracts worth ₹5.65 crore for equipment and utilities. This total project outlay of ₹10 crore is highly material, representing approximately 67% of the company's TTM revenue of ₹15 crore. The board also approved Q1 FY27 results and is currently negotiating with banks to secure funding for the project.
Confidence: HIGH
What changedThe company has moved from planning to active execution of a major facility upgrade, with nearly half the projected capital already deployed or committed.
Why it mattersCompliance with Revised Schedule M is a regulatory necessity in pharma; the scale of this investment relative to the company's size suggests a significant modernization that could enhance operational capabilities.
Total Project Outlay: ₹10 crAmount Spent to Date: ₹4.35 crNew Capital Contracts: ₹5.65 crProject vs TTM Revenue: ~67%Project vs Market Cap: ~43%
📅 Short termThe market may react positively to the scale of the upgrade, though the impact of Q1 FY27 results (approved but not detailed in text) will be the immediate driver.
📈 Long termIf successfully funded and executed, this upgrade modernizes the asset base of a micro-cap company, though it will likely introduce debt to a currently debt-free balance sheet.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Funding risk (bank negotiations ongoing)
- Execution risk of manufacturing upgrade
- Potential increase in leverage for a micro-cap
Key Highlights
₹435 lakh (₹4.35 cr) already spent towards renovation and construction of new blocks
₹565 lakh (₹5.65 cr) in capital contracts and orders issued for utilities and equipment
Total project visibility of ₹10 cr represents ~67% of TTM revenue and ~43% of market cap
Construction of a new warehouse block has been completed as part of the ongoing upgrade
Board approved re-appointment of promoter-director Mrs. Abha Agrawal post attaining age 75
👀 What to Watch
Watch for the successful closure of bank financing negotiations and the completion timeline for the remaining civil works on existing buildings.
